The expanding role of pertuzumab in the treatment of HER2-positive breast cancer

I Moya-Horno,1 J Cortés1,2 1Department of Medical Oncology, Instituto Oncológico Baselga, Hospital Quirón, 2Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain Abstract: Breast cancer tumors that demonstrate gene amplificatio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Moya-Horno I, Cortés J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/4330ba2b64314281afb0b2ecbad96dc8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4330ba2b64314281afb0b2ecbad96dc8
record_format	dspace
spelling	oai:doaj.org-article:4330ba2b64314281afb0b2ecbad96dc82021-12-02T00:39:06ZThe expanding role of pertuzumab in the treatment of HER2-positive breast cancer1179-1314https://doaj.org/article/4330ba2b64314281afb0b2ecbad96dc82015-05-01T00:00:00Zhttp://www.dovepress.com/the-expanding-role-of-pertuzumab-in-the-treatment-of-her2-positive-bre-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314I Moya-Horno,1 J Cortés1,2 1Department of Medical Oncology, Instituto Oncológico Baselga, Hospital Quirón, 2Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain Abstract: Breast cancer tumors that demonstrate gene amplification or overexpression of human epidermal growth factor receptor 2 (HER2) are classified as HER2-positive. They account for approximately 15% of all breast cancers and represent an adverse prognostic factor. Over the past years, many new therapies have become available for the treatment of breast cancer. Particularly, the treatment of patients with HER2-positive breast cancer has developed with the arrival of anti-HER2 targeted therapies that have been proven to increase survival in both the metastatic and early-stage settings of the disease. Trastuzumab, a monoclonal antibody targeting HER2, significantly improves survival in HER2-positive breast cancer. Nevertheless, it is still a challenge to evolve anti-HER2 therapies, as the disease may progress. Pertuzumab inhibits HER2 by binding to a different HER2 epitope than trastuzumab and represents a complementary mechanism of action to trastuzumab. The efficacy and safety of pertuzumab in combination with trastuzumab with or without chemotherapy have been demonstrated in both advanced and early stages of HER2-positive breast cancer. Herein, we review the available data on the use of pertuzumab for the treatment of patients with HER2-positive breast cancer. Keywords: pertuzumab, anti-HER2 targeted therapies, HER2-positive breast cancer Moya-Horno ICortés JDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2015, Iss default, Pp 125-132 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Moya-Horno I Cortés J The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
description	I Moya-Horno,1 J Cortés1,2 1Department of Medical Oncology, Instituto Oncológico Baselga, Hospital Quirón, 2Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain Abstract: Breast cancer tumors that demonstrate gene amplification or overexpression of human epidermal growth factor receptor 2 (HER2) are classified as HER2-positive. They account for approximately 15% of all breast cancers and represent an adverse prognostic factor. Over the past years, many new therapies have become available for the treatment of breast cancer. Particularly, the treatment of patients with HER2-positive breast cancer has developed with the arrival of anti-HER2 targeted therapies that have been proven to increase survival in both the metastatic and early-stage settings of the disease. Trastuzumab, a monoclonal antibody targeting HER2, significantly improves survival in HER2-positive breast cancer. Nevertheless, it is still a challenge to evolve anti-HER2 therapies, as the disease may progress. Pertuzumab inhibits HER2 by binding to a different HER2 epitope than trastuzumab and represents a complementary mechanism of action to trastuzumab. The efficacy and safety of pertuzumab in combination with trastuzumab with or without chemotherapy have been demonstrated in both advanced and early stages of HER2-positive breast cancer. Herein, we review the available data on the use of pertuzumab for the treatment of patients with HER2-positive breast cancer. Keywords: pertuzumab, anti-HER2 targeted therapies, HER2-positive breast cancer
format	article
author	Moya-Horno I Cortés J
author_facet	Moya-Horno I Cortés J
author_sort	Moya-Horno I
title	The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
title_short	The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
title_full	The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
title_fullStr	The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
title_full_unstemmed	The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
title_sort	expanding role of pertuzumab in the treatment of her2-positive breast cancer
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/4330ba2b64314281afb0b2ecbad96dc8
work_keys_str_mv	AT moyahornoi theexpandingroleofpertuzumabinthetreatmentofher2positivebreastcancer AT cortesj theexpandingroleofpertuzumabinthetreatmentofher2positivebreastcancer AT moyahornoi expandingroleofpertuzumabinthetreatmentofher2positivebreastcancer AT cortesj expandingroleofpertuzumabinthetreatmentofher2positivebreastcancer
_version_	1718403549153460224

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer

Ejemplares similares